Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2014

View Archived Issues

New consortium to develop PDE inhibitors for neglected parasitic diseases

CalciMedica patent divulges novel Ca2+ channel modulators

Daiichi Sankyo and UCSF collaborate on drugs for neurodegenerative diseases

New murine models created to investigate type 1 hereditary hemorrhagic telangiectasia

US Oncology Research teams up with Corcept Therapeutics for mifepristone trial

MK-5172/MK-8742 combination effective in phase II C-WORTHY trial

Pfizer reports discovery of novel CRTH2 antagonists

Glenmark Pharmaceuticals' GRC-27864 enters human trials

Dyax receives FDA approval to expand the use of Kalbitor

Amgen reports topline results from phase III study of talimogene laherparepvec

Roche patent reports new FABP inhibitors

New BTK inhibitors designed by KBP BioSciences

ViiV Healthcare and MPP to improve access to dolutegravir

Scientists at Nanjing Sanhome Pharmaceutical disclose novel BCR-ABL1 inhibitors

Co-formulation of migalastat HCl and alpha-Gal A enhances stability and potency of the enzyme

Santen's SAKURA study meets primary endpoint in posterior segment uveitis

FDA approves Evzio for the emergency treatment of opioid overdose

MT-3724 shows significant antitumor activity in vitro and in vivo

Halozyme suspends enrollment and dosing in phase II trial of PEGPH-20 for pancreatic cancer

New START2 trial investigates tecemotide in stage III NSCLC

Genzyme to resubmit Lemtrada sBLA in U.S.

FDA extends PDUFA date for Afrezza review

Cellular Biomedicine initiates phase IIb trial of cell therapy for knee osteoarthritis

FDA awards breakthrough therapy designation to Bexsero

Preclinical efficacy of novel PDE10A inhibitors suggests potential for schizophrenia therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...